Log in
NASDAQ:CDLX

Cardlytics Competitors

$75.60
-3.02 (-3.84 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$75.35
Now: $75.60
$80.00
50-Day Range
$64.26
MA: $74.45
$85.11
52-Week Range
$27.33
Now: $75.60
$107.50
Volume390,534 shs
Average Volume724,453 shs
Market Capitalization$2.06 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.34

Competitors

Cardlytics (NASDAQ:CDLX) Vs. DOYU, HUYA, MDLA, SWCH, SVMK, and VNET

Should you be buying CDLX stock or one of its competitors? Companies in the industry of "computer programming, data processing, & other computer related" are considered alternatives and competitors to Cardlytics, including DouYu International (DOYU), HUYA (HUYA), Medallia (MDLA), Switch (SWCH), SVMK (SVMK), and 21Vianet Group (VNET).

DouYu International (NASDAQ:DOYU) and Cardlytics (NASDAQ:CDLX) are both mid-cap consumer discretionary companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.

Valuation & Earnings

This table compares DouYu International and Cardlytics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DouYu International$1.04 billion4.61$5.68 million$0.04378.25
Cardlytics$210.43 million9.80$-17,140,000.00($0.75)-100.80

DouYu International has higher revenue and earnings than Cardlytics. Cardlytics is trading at a lower price-to-earnings ratio than DouYu International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DouYu International and Cardlytics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DouYu International6.84%8.41%6.66%
Cardlytics-18.86%-26.42%-17.67%

Volatility & Risk

DouYu International has a beta of 1.76, indicating that its share price is 76% more volatile than the S&P 500. Comparatively, Cardlytics has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for DouYu International and Cardlytics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DouYu International03102.25
Cardlytics23101.83

DouYu International presently has a consensus price target of $11.1750, indicating a potential downside of 26.14%. Cardlytics has a consensus price target of $58.50, indicating a potential downside of 22.62%. Given Cardlytics' higher possible upside, analysts plainly believe Cardlytics is more favorable than DouYu International.

Insider and Institutional Ownership

12.9% of DouYu International shares are held by institutional investors. Comparatively, 91.4% of Cardlytics shares are held by institutional investors. 6.5% of Cardlytics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

DouYu International beats Cardlytics on 8 of the 13 factors compared between the two stocks.

HUYA (NYSE:HUYA) and Cardlytics (NASDAQ:CDLX) are both mid-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares HUYA and Cardlytics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUYA$1.20 billion3.99$67.25 million$0.2975.86
Cardlytics$210.43 million9.80$-17,140,000.00($0.75)-100.80

HUYA has higher revenue and earnings than Cardlytics. Cardlytics is trading at a lower price-to-earnings ratio than HUYA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares HUYA and Cardlytics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HUYA6.92%7.63%5.91%
Cardlytics-18.86%-26.42%-17.67%

Risk and Volatility

HUYA has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Cardlytics has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for HUYA and Cardlytics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HUYA02702.78
Cardlytics23101.83

HUYA presently has a consensus price target of $22.6250, indicating a potential upside of 2.84%. Cardlytics has a consensus price target of $58.50, indicating a potential downside of 22.62%. Given HUYA's stronger consensus rating and higher possible upside, equities analysts clearly believe HUYA is more favorable than Cardlytics.

Insider & Institutional Ownership

30.2% of HUYA shares are held by institutional investors. Comparatively, 91.4% of Cardlytics shares are held by institutional investors. 6.5% of Cardlytics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

HUYA beats Cardlytics on 10 of the 14 factors compared between the two stocks.

Medallia (NYSE:MDLA) and Cardlytics (NASDAQ:CDLX) are both mid-cap computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Medallia and Cardlytics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medallia$402.46 million10.81$-112,330,000.00($1.35)-21.92
Cardlytics$210.43 million9.80$-17,140,000.00($0.75)-100.80

Cardlytics has lower revenue, but higher earnings than Medallia. Cardlytics is trading at a lower price-to-earnings ratio than Medallia, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medallia and Cardlytics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medallia-31.54%-30.19%-17.38%
Cardlytics-18.86%-26.42%-17.67%

Risk and Volatility

Medallia has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, Cardlytics has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Medallia and Cardlytics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medallia02802.80
Cardlytics23101.83

Medallia presently has a consensus price target of $36.20, indicating a potential upside of 22.34%. Cardlytics has a consensus price target of $58.50, indicating a potential downside of 22.62%. Given Medallia's stronger consensus rating and higher possible upside, equities analysts clearly believe Medallia is more favorable than Cardlytics.

Insider & Institutional Ownership

87.1% of Medallia shares are held by institutional investors. Comparatively, 91.4% of Cardlytics shares are held by institutional investors. 6.5% of Cardlytics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Switch (NYSE:SWCH) and Cardlytics (NASDAQ:CDLX) are both mid-cap business services companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Switch and Cardlytics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Switch$462.31 million7.67$8.92 million$0.1598.20
Cardlytics$210.43 million9.80$-17,140,000.00($0.75)-100.80

Switch has higher revenue and earnings than Cardlytics. Cardlytics is trading at a lower price-to-earnings ratio than Switch, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Switch has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Cardlytics has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500.

Insider & Institutional Ownership

34.4% of Switch shares are held by institutional investors. Comparatively, 91.4% of Cardlytics shares are held by institutional investors. 30.5% of Switch shares are held by company insiders. Comparatively, 6.5% of Cardlytics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Switch and Cardlytics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Switch2.03%2.72%0.96%
Cardlytics-18.86%-26.42%-17.67%

Analyst Ratings

This is a summary of recent recommendations and price targets for Switch and Cardlytics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Switch01713.00
Cardlytics23101.83

Switch presently has a consensus price target of $20.9375, indicating a potential upside of 42.14%. Cardlytics has a consensus price target of $58.50, indicating a potential downside of 22.62%. Given Switch's stronger consensus rating and higher possible upside, equities analysts clearly believe Switch is more favorable than Cardlytics.

Summary

Switch beats Cardlytics on 12 of the 15 factors compared between the two stocks.

SVMK (NASDAQ:SVMK) and Cardlytics (NASDAQ:CDLX) are both mid-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Earnings & Valuation

This table compares SVMK and Cardlytics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SVMK$307.42 million9.64$-73,860,000.00($0.56)-37.73
Cardlytics$210.43 million9.80$-17,140,000.00($0.75)-100.80

Cardlytics has lower revenue, but higher earnings than SVMK. Cardlytics is trading at a lower price-to-earnings ratio than SVMK, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

SVMK has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Cardlytics has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500.

Insider and Institutional Ownership

77.4% of SVMK shares are owned by institutional investors. Comparatively, 91.4% of Cardlytics shares are owned by institutional investors. 18.7% of SVMK shares are owned by insiders. Comparatively, 6.5% of Cardlytics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares SVMK and Cardlytics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SVMK-24.73%-27.64%-10.48%
Cardlytics-18.86%-26.42%-17.67%

Analyst Recommendations

This is a summary of recent ratings and price targets for SVMK and Cardlytics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SVMK01502.83
Cardlytics23101.83

SVMK currently has a consensus price target of $27.1667, indicating a potential upside of 28.57%. Cardlytics has a consensus price target of $58.50, indicating a potential downside of 22.62%. Given SVMK's stronger consensus rating and higher possible upside, research analysts clearly believe SVMK is more favorable than Cardlytics.

Summary

SVMK beats Cardlytics on 8 of the 14 factors compared between the two stocks.

21Vianet Group (NASDAQ:VNET) and Cardlytics (NASDAQ:CDLX) are both mid-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Earnings & Valuation

This table compares 21Vianet Group and Cardlytics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
21Vianet Group$544.25 million4.80$-26,180,000.00($0.24)-96.42
Cardlytics$210.43 million9.80$-17,140,000.00($0.75)-100.80

Cardlytics has lower revenue, but higher earnings than 21Vianet Group. Cardlytics is trading at a lower price-to-earnings ratio than 21Vianet Group, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

21Vianet Group has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Cardlytics has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500.

Insider and Institutional Ownership

44.1% of 21Vianet Group shares are owned by institutional investors. Comparatively, 91.4% of Cardlytics shares are owned by institutional investors. 12.1% of 21Vianet Group shares are owned by insiders. Comparatively, 6.5% of Cardlytics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares 21Vianet Group and Cardlytics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
21Vianet Group-55.01%-49.02%-15.31%
Cardlytics-18.86%-26.42%-17.67%

Analyst Recommendations

This is a summary of recent ratings and price targets for 21Vianet Group and Cardlytics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
21Vianet Group00603.00
Cardlytics23101.83

21Vianet Group currently has a consensus price target of $24.2667, indicating a potential upside of 4.87%. Cardlytics has a consensus price target of $58.50, indicating a potential downside of 22.62%. Given 21Vianet Group's stronger consensus rating and higher possible upside, research analysts clearly believe 21Vianet Group is more favorable than Cardlytics.

Summary

21Vianet Group beats Cardlytics on 8 of the 14 factors compared between the two stocks.


Cardlytics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
DOYU
DouYu International
1.1$15.13-5.6%$4.80 billion$1.04 billion63.04
HUYA logo
HUYA
HUYA
1.3$22.00-5.5%$4.80 billion$1.20 billion53.66Increase in Short Interest
MDLA
Medallia
1.6$29.59-1.4%$4.35 billion$402.46 million-28.18Insider Selling
Switch logo
SWCH
Switch
1.5$14.73-0.5%$3.54 billion$462.31 million147.31Upcoming Earnings
SVMK logo
SVMK
SVMK
1.5$21.13-1.1%$2.96 billion$307.42 million-33.54Upcoming Earnings
Increase in Short Interest
21Vianet Group logo
VNET
21Vianet Group
1.1$23.14-2.2%$2.61 billion$544.25 million-7.82Increase in Short Interest
TripAdvisor logo
TRIP
TripAdvisor
1.6$19.40-3.5%$2.61 billion$1.56 billion-24.56Upcoming Earnings
Pluralsight logo
PS
Pluralsight
1.5$16.80-1.3%$2.43 billion$316.91 million-14.36Upcoming Earnings
Sabre logo
SABR
Sabre
1.5$6.54-4.4%$1.80 billion$3.97 billion-3.08Upcoming Earnings
Analyst Downgrade
HCAT
Health Catalyst
1.4$34.48-1.5%$1.37 billion$154.94 million-11.61Analyst Upgrade
Model N logo
MODN
Model N
1.3$35.17-0.5%$1.22 billion$141.24 million-74.83
Eventbrite logo
EB
Eventbrite
1.2$9.81-1.3%$891.24 million$326.80 million-3.67Upcoming Earnings
QTT
Qutoutiao
1.3$2.30-3.0%$651.54 million$790.85 million-1.95
HealthStream logo
HSTM
HealthStream
1.0$18.34-0.9%$586.83 million$254.11 million33.35Earnings Announcement
Analyst Report
Analyst Revision
TrueCar logo
TRUE
TrueCar
1.1$4.55-0.2%$491.44 million$353.88 million-13.00Upcoming Earnings
Increase in Short Interest
JG
Aurora Mobile
0.5$1.77-6.2%$204.92 million$130.21 million-8.85High Trading Volume
Sify Technologies logo
SIFY
Sify Technologies
1.1$1.07-0.0%$190.87 million$326.31 million0.00Decrease in Short Interest
Jianpu Technology logo
JT
Jianpu Technology
1.0$0.56-3.5%$95.28 million$234.18 million-1.88Stock Split
LIZI
Phoenix Tree
1.5$2.04-1.0%$93.30 million$169.58 million0.00
Synacor logo
SYNC
Synacor
0.5$1.42-2.8%$56.03 million$121.85 million-4.73Upcoming Earnings
Decrease in Short Interest
Autoweb logo
AUTO
Autoweb
1.6$3.40-5.3%$44.70 million$113.98 million-4.36Upcoming Earnings
PT
Pintec Technology
0.6$0.87-3.5%$32.47 million$184.61 million0.00
GIGM
GigaMedia
1.2$2.80-0.7%$30.95 million$6.64 million-28.00
CNET
Chinanet Online
0.5$1.42-1.4%$30.87 million$58.08 million-10.92Decrease in Short Interest
MOXC
Moxian
0.3$1.15-4.3%$18.62 million$370,000.000.00
Professional Diversity Network logo
IPDN
Professional Diversity Network
0.4$1.04-0.0%$13.33 million$5.03 million0.00
This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.